Notably, 50.7% of participants receiving CagriSema reached the BMI threshold for non-obesity by the end of the trial, compared with 10.2% of the placebo group
Legal Disclaimer: The bundle (Tesamorelin & Ipamorelin Blend, BPC-157 & TB-500 Blend) is sold by Protide Health for laboratory research purposes only
That single line protects both you and the vendor
I don't want to
The authors themselves described it as a small preliminary study.[15] A 2025 pilot report described intravenous administration to two healthy adults at doses up to 20 mg, with no measurable changes in cardiac, hepatic, renal or thyroid biomarkers and no reported adverse effects.[16] Two individuals cannot characterise uncommon reactions, immunogenicity, long-term toxicity, reproductive safety or oncological risk
This immunomodulatory activity helps transition tissues from acute inflammatory phases to productive repair states